NCT00126841

Brief Summary

Patients with more advanced stages of cervix cancer are treated by radiotherapy. Overall, more than 50% are cured. Approximately half of those patients not cured have current cancer in the irradiated volume. Higher doses of radiation would be expected to cure more patients. To give high doses of radiation safely, the investigators need to know very precisely where the cancer is and then they can use new technology available at the Cross Cancer Institute (tomotherapy) to target the cancer precisely, giving higher doses to the cancerous tissues and lower doses to the non-cancerous tissues. This study of ten patients with cervical cancer will investigate the added value of MRI scanning on precise tumor definition to facilitate more accurate radiotherapy treatment planning. For this study, patients will be treated in the conventional way with conventional doses. The investigators hope that treatment for future patients will be planned with MRI data and that they will be treated to higher doses of tomotherapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2004

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2004

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

August 3, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 5, 2005

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2005

Completed
Last Updated

December 9, 2011

Status Verified

December 1, 2011

First QC Date

August 3, 2005

Last Update Submit

December 8, 2011

Conditions

Keywords

radiotherapy planning CT/MR fusion

Interventions

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

primary care clinic

You may qualify if:

  • Cervical cancer undergoing primary radiotherapy

You may not qualify if:

  • Stage 1B
  • Patient refusal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada

Location

Related Publications (9)

  • Subak LL, Hricak H, Powell CB, Azizi L, Stern JL. Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol. 1995 Jul;86(1):43-50. doi: 10.1016/0029-7844(95)00109-5.

    PMID: 7784021BACKGROUND
  • Ozsarlak O, Tjalma W, Schepens E, Corthouts B, Op de Beeck B, Van Marck E, Parizel PM, De Schepper AM. The correlation of preoperative CT, MR imaging, and clinical staging (FIGO) with histopathology findings in primary cervical carcinoma. Eur Radiol. 2003 Oct;13(10):2338-45. doi: 10.1007/s00330-003-1928-2. Epub 2003 Jun 12.

    PMID: 12802611BACKGROUND
  • Kim SH, Choi BI, Han JK, Kim HD, Lee HP, Kang SB, Lee JY, Han MC. Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients. J Comput Assist Tomogr. 1993 Jul-Aug;17(4):633-40. doi: 10.1097/00004728-199307000-00022.

    PMID: 8331236BACKGROUND
  • Ho CM, Chien TY, Jeng CM, Tsang YM, Shih BY, Chang SC. Staging of cervical cancer: comparison between magnetic resonance imaging, computed tomography and pelvic examination under anesthesia. J Formos Med Assoc. 1992 Oct;91(10):982-90.

    PMID: 1362678BACKGROUND
  • Bipat S, Glas AS, van der Velden J, Zwinderman AH, Bossuyt PM, Stoker J. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. Gynecol Oncol. 2003 Oct;91(1):59-66. doi: 10.1016/s0090-8258(03)00409-8.

    PMID: 14529663BACKGROUND
  • Scheidler J, Hricak H, Yu KK, Subak L, Segal MR. Radiological evaluation of lymph node metastases in patients with cervical cancer. A meta-analysis. JAMA. 1997 Oct 1;278(13):1096-101.

    PMID: 9315770BACKGROUND
  • Knocke TH, Pokrajac B, Fellner C, Potter R. [A comparison of CT-supported 3D planning with simulator planning in the pelvic irradiation of primary cervical carcinoma]. Strahlenther Onkol. 1999 Feb;175(2):68-73. doi: 10.1007/BF02753845. German.

    PMID: 10065141BACKGROUND
  • Wachter-Gerstner N, Wachter S, Reinstadler E, Fellner C, Knocke TH, Potter R. The impact of sectional imaging on dose escalation in endocavitary HDR-brachytherapy of cervical cancer: results of a prospective comparative trial. Radiother Oncol. 2003 Jul;68(1):51-9. doi: 10.1016/s0167-8140(03)00083-5.

    PMID: 12885452BACKGROUND
  • Krempien RC, Daeuber S, Hensley FW, Wannenmacher M, Harms W. Image fusion of CT and MRI data enables improved target volume definition in 3D-brachytherapy treatment planning. Brachytherapy. 2003;2(3):164-71. doi: 10.1016/S1538-4721(03)00133-8.

    PMID: 15062139BACKGROUND

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Robert Pearcey, MD

    AHS Cancer Control Alberta

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 3, 2005

First Posted

August 5, 2005

Study Start

November 1, 2004

Study Completion

November 1, 2005

Last Updated

December 9, 2011

Record last verified: 2011-12

Locations